MOSAIC

Study Title: Immunogenicity and adverse events following immunization (AEFI) with alternate schedules of COVID-19 vaccines in Canada: is “mix and match” of the second dose (MOSAIC-1;CT24a) and additional doses (MOSAIC-2 and MOSAIC-3;CT24b and CT24c) safe and immunogenic?

The purpose of the MOSAIC studies is to find out how long vaccine protection against COVID-19 lasts, and how safe and effective it is to use different vaccine products. As Canada continues to roll out COVID-19 immunization programs with a focus on additional (“booster”) doses for all eligible Canadians, MOSAIC is studying how well 3rd and 4th doses can provide long-term protection.

MOSAIC is designed to provide public health with up-to-the-minute information on how well and for how long these boosters provide protection against COVID-19. To keep pace with public health programs, researchers are urgently seeking participants in Vancouver, Penticton, Quebec City and Halifax who have not yet received a COVID-19 booster.

All the vaccines used in this study are authorized for use in public health programs in Canada during the COVID-19 pandemic.

MOSAIC 3 – 4th COVID-19 Vaccine Dose
Start Date: July 2022
ENROLLING SOON

MOSAIC 3 will evaluate the safety, tolerability and immune response to a fourth dose of a COVID-19 vaccine currently authorized in Canada (either the Pfizer-BioNTech or Moderna mRNA vaccine or the Medicago VLP vaccine) in persons who received their last COVID-19 vaccine at least 3 (three) months ago

Eligibility – CURRENTLY ENROLLING

You can take part in this study if:

  1. You are 18 years of age and older
  2. You are available for all the study visits.
  3. You are in good health with stable health conditions.
  4. You are not pregnant.
  5. You have a record of your previous doses of the authorized COVID-19 vaccines you received.

There are other study criteria that will be reviewed at the first visit to determine if you are eligible or not.

Learn more about MOSAIC 3 | Click here to contact the study team nearest you

MOSAIC 2 – 3rd COVID-19 Vaccine Dose
Start Date: January 2021
CURRENTLY ENROLLING

As of July 2022, MOSAIC 2 has added a new study arm to include the use of Medicago VLP as a booster dose.

MOSAIC 2 will evaluate the safety, tolerability and immune response to a third dose of a COVID-19 vaccine currently authorized in Canada (either the Pfizer-BioNTech or Moderna mRNA vaccine) in persons who received both doses of their first COVID-19 vaccines at least 6 (six) months ago.  Approximately 400 participants are taking part. A Medicago VLP vaccine group is being added.  We hope to enroll 100 to 150 participants in this group.

Eligibility – ENROLLING FOR MEDICAGO AS 3RD DOSE ONLY

You can take part in this study if:

  1. You are 30+ years old
  2. You are available for all the study visits.
  3. You are in good health with stable health conditions.
  4. You are not pregnant.
  5. You have a record of the first two doses of the authorized COVID-19 vaccines you received.

There are other study criteria that will be reviewed at the first visit to determine if you are eligible or not.

Learn more about MOSAIC 2 | Click here to contact the study team nearest you

 

MOSAIC 1 – Mix-and-Match of the First and Second COVID-19 Vaccine Dose
Start Date: June 2021
CURRENTLY ENROLLING

The initial MOSAIC study was commenced to compare the effectiveness, safety and acceptability of different dosing schedules of the first two doses of COVID-19 vaccines. That study began in June 2021 and is ongoing at 7 clinical sites in Canada where 195 participants were enrolled and received either both of their vaccines or the second authorized COVID-19 vaccine. Assessment of the safety, tolerability and immune response in these participants is ongoing.

Eligibility – ENROLLMENT NOW CLOSED

You can take part in this study if:

  1. You are 18 years of age and older
  2. You are available for all the study visits.
  3. You are in good health with stable health conditions.
  4. You are not pregnant.
  5. You have a record of your previous doses of the authorized COVID-19 vaccines you received.

Learn more about MOSAIC 1

Principle Investigators

Dr. Joanne Langley

Dr. Joanne Langley is a Professor of Pediatrics and Community Health and Epidemiology at Dalhousie University and the Canadian Center for Vaccinology in Halifax, NS Canada, head of Pediatric Infectious Diseases at the IWK Health Centre, and lead for the Clinical Trials Network of the Canadian Immunization Research Network. She currently co-chairs the Canadian COVID-19 Vaccine Task Force. Her research is focused on the epidemiology and vaccine prevention of respiratory infections, particularly Respiratory Syncytial Virus and influenza, and immunization decision-making.

Partners & Sponsors

About the COVID Immunity Task Force (CITF)

In late April 2020, the Government of Canada established the COVID-19 Immunity Task Force with a two-year mandate. The Task Force is overseen by a Leadership Group of volunteers that includes leading Canadian scientists and experts from universities and healthcare facilities across Canada who are focused on understanding the nature of immunity arising from the novel coronavirus that causes COVID-19. To that end, the CITF is supporting numerous studies to determine the extent of SARS-CoV-2 infection in Canada (in the general population as well as in specific communities and priority populations), understand the nature of immunity following infection, develop improved antibody testing methods, and help monitor the effectiveness and safety of vaccines as they are rolled out across Canada. The Task Force and its Secretariat accordingly work closely with a range of partners, including governments, public health agencies, institutions, health organizations, research teams, other task forces, and engages communities and stakeholders. Most recently, the Task Force has been asked to support vaccine surveillance, effectiveness and safety as part of its overall objective to generate data and ideas that inform interventions aimed at slowing – and ultimately stopping – the spread of SARS-CoV-2 in Canada. For more information visit: www.covid19immunitytaskforce.ca

About the Vaccine Surveillance Reference Group

The Vaccine Surveillance Reference Group (VSRG) supports the monitoring of the safety and effectiveness of COVID-19 vaccines in Canada. It is a consortium of Canadian organizations – the Public Health Agency of Canada (PHAC), the Canadian Research Immunization Network (CIRN), the National Advisory Committee on Immunization (NACI) and the COVID-19 Immunity Task Force (CITF) – working collaboratively to pool expertise on vaccine surveillance. The VSRG reports to the President of the Public Health Agency of Canada (PHAC) and is supported by the COVID-19 Immunity Task Force (CITF) Secretariat. It is co-chaired by the leaders of the National Advisory Committee on Immunization (NACI) and the Canadian Immunization Research Network (CIRN). Among its responsibilities, the VSRG, through the CITF Executive Committee, makes recommendations to PHAC on funding research teams that can address important aspects of the immune response, safety, and effectiveness of COVID-19 vaccines with public health relevance and with attention to all priority groups. For more information visit: covid19immunitytaskforce.ca/vaccine-surveillance-reference-group-vsrg/

About Dalhousie University

Dalhousie University is Atlantic Canada’s leading research-intensive university. Located in the heart of Halifax, Nova Scotia, with an Agricultural Campus in Truro/Bible Hill, Dalhousie is a truly national and international university, with more than half of the university’s 20,000-plus students coming from outside the province. Dal’s 6,000 faculty and staff foster a diverse, purpose-driven community, one that spans 13 faculties and conducts more than $181 million in research annually. Part of a cluster identified as one of the world’s top international centers in ocean research, the university proudly celebrated its 200th anniversary in 2018.